These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 20072835)

  • 21. Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor.
    Isfort S; Crysandt M; Gezer D; Koschmieder S; Brümmendorf TH; Wolf D
    Recent Results Cancer Res; 2018; 212():87-108. PubMed ID: 30069626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
    Kantarjian HM; Cortes JE; Kim DW; Khoury HJ; Brümmendorf TH; Porkka K; Martinelli G; Durrant S; Leip E; Kelly V; Turnbull K; Besson N; Gambacorti-Passerini C
    Blood; 2014 Feb; 123(9):1309-18. PubMed ID: 24345751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib.
    Redaelli S; Boschelli F; Perini P; Pirola A; Viltadi M; Gambacorti-Passerini C
    Leukemia; 2010 Jun; 24(6):1223-7. PubMed ID: 20445575
    [No Abstract]   [Full Text] [Related]  

  • 24. [Pharmacology profile and clinical findings of bosutinib hydrate (Bosulif® Tablets)].
    Tahara M; Shibata A; Katsura S
    Nihon Yakurigaku Zasshi; 2016 May; 147(5):311-8. PubMed ID: 27181728
    [No Abstract]   [Full Text] [Related]  

  • 25. An update on dual Src/Abl inhibitors.
    Musumeci F; Schenone S; Brullo C; Botta M
    Future Med Chem; 2012 Apr; 4(6):799-822. PubMed ID: 22530642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [New treatment option for patient with CML-bosutinib].
    Takahashi N
    Gan To Kagaku Ryoho; 2015 May; 42(5):563-7. PubMed ID: 26054091
    [No Abstract]   [Full Text] [Related]  

  • 27. Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.
    Hall KH; Brooks A; Waller EK
    Am J Hematol; 2021 Aug; 96(8):E293-E295. PubMed ID: 33971041
    [No Abstract]   [Full Text] [Related]  

  • 28. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia.
    Trask PC; Cella D; Besson N; Kelly V; Masszi T; Kim DW
    Leuk Res; 2012 Apr; 36(4):438-42. PubMed ID: 22036634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
    Puttini M; Coluccia AM; Boschelli F; Cleris L; Marchesi E; Donella-Deana A; Ahmed S; Redaelli S; Piazza R; Magistroni V; Andreoni F; Scapozza L; Formelli F; Gambacorti-Passerini C
    Cancer Res; 2006 Dec; 66(23):11314-22. PubMed ID: 17114238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606.
    Mancini M; Brusa G; Zuffa E; Corrado P; Martinelli G; Grafone T; Barbieri E; Santucci MA
    Leuk Res; 2007 Jul; 31(7):979-87. PubMed ID: 17129604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia.
    Kantarjian HM; Jabbour EJ; Lipton JH; Castagnetti F; Brümmendorf TH
    Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):285-297. PubMed ID: 38278737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib.
    Abbas R; Hsyu PH
    Clin Pharmacokinet; 2016 Oct; 55(10):1191-1204. PubMed ID: 27113346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
    Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
    Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bosutinib more effective than imatinib in CML.
    Gourd E
    Lancet Oncol; 2017 Dec; 18(12):e716. PubMed ID: 29129440
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial.
    Chuah C; Koh LP; Numbenjapon T; Zang DY; Ong KH; Do YR; Ohkura M; Ono C; Viqueira A; Cortes JE; Brümmendorf TH
    Int J Hematol; 2021 Jul; 114(1):65-78. PubMed ID: 33851349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
    Melo JV; Chuah C
    Hematology Am Soc Hematol Educ Program; 2008; ():427-35. PubMed ID: 19074121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.
    Bieerkehazhi S; Chen Z; Zhao Y; Yu Y; Zhang H; Vasudevan SA; Woodfield SE; Tao L; Yi JS; Muscal JA; Pang JC; Guan S; Zhang H; Nuchtern JG; Li H; Li H; Yang J
    Oncotarget; 2017 Jan; 8(1):1469-1480. PubMed ID: 27903968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bosutinib treatment for Philadelphia chromosome-positive leukemias.
    Bethelmie-Bryan B; Lord K; Holloway S; Khoury HJ
    Future Oncol; 2014 Feb; 10(2):179-85. PubMed ID: 24490604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia.
    Nakaseko C; Takahashi N; Ishizawa K; Kobayashi Y; Ohashi K; Nakagawa Y; Yamamoto K; Miyamura K; Taniwaki M; Okada M; Kawaguchi T; Shibata A; Fujii Y; Ono C; Ohnishi K
    Int J Hematol; 2015 Feb; 101(2):154-64. PubMed ID: 25540064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.
    Daud AI; Krishnamurthi SS; Saleh MN; Gitlitz BJ; Borad MJ; Gold PJ; Chiorean EG; Springett GM; Abbas R; Agarwal S; Bardy-Bouxin N; Hsyu PH; Leip E; Turnbull K; Zacharchuk C; Messersmith WA
    Clin Cancer Res; 2012 Feb; 18(4):1092-100. PubMed ID: 22179664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.